International Generosity Foundation Trust (BRNS) discloses 6.7% Barinthus Biotherapeutics holding

Rhea-AI Filing Summary

International Generosity Foundation Trust, a Florida-based non-profit trust, reported beneficial ownership of Barinthus Biotherapeutics plc common stock. It holds 2,734,189 shares, representing 6.7% of the outstanding common stock, with sole voting and sole dispositive power over all of these shares.

The trust acquired the position through a mix of purchases funded by its working capital and transfers or contributions it received, reflecting both investment and charitable purposes. It states it may buy more shares or sell some or all holdings over time, including to support its charitable activities, but reports no transactions in the issuer’s securities during the past 60 days and no special contracts or arrangements relating to the stock.

Insights

Equity ownership analyst

Non-profit trust discloses a 6.7% passive-style stake in Barinthus.

The filing shows International Generosity Foundation Trust owns 2,734,189 Barinthus Biotherapeutics shares, or 6.7% of the common stock, with sole voting and dispositive power. The trust is a Section 501(c) non-profit funded by donations and working capital.

The position was accumulated via purchases and contributed shares, and is held for investment and charitable purposes. The trust notes it may increase or decrease its holdings depending on conditions but reports no trades in the last 60 days and no special agreements related to the stock.

Key Figures

Shares beneficially owned: 2,734,189 shares Ownership percentage: 6.7% Sole voting power: 2,734,189 shares +2 more

5 metrics

Shares beneficially owned 2,734,189 shares Common stock beneficially owned by International Generosity Foundation Trust

Ownership percentage 6.7% Percent of Barinthus Biotherapeutics common stock class represented by the trust’s holdings

Sole voting power 2,734,189 shares Shares over which the trust has sole voting power

Sole dispositive power 2,734,189 shares Shares over which the trust has sole dispositive power

Event date 02/03/2026 Date of event requiring the Schedule 13D filing

Key Terms

beneficially owned, sole voting power, sole dispositive power, Schedule 13D, +1 more

5 terms

beneficially owned financial

"Aggregate amount beneficially owned by each reporting person 2,734,189.00"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"Number of Shares Beneficially Owned by Each Reporting Person With: | 7 | Sole Voting Power 2,734,189.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"9 | Sole Dispositive Power 2,734,189.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Schedule 13D regulatory

"If the filing person has previously filed a statement on Schedule 13G to report the acquisition"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

donor-advised funds financial

"The Reporting Person is a non-profit trust generally funded through donations, including donor-advised funds."

A donor-advised fund is a charitable “giving account” that lets a person or family give cash or securities to a fund, get an immediate tax benefit, and then recommend when and which charities receive grants over time. For investors this matters because it changes the timing and form of charitable selling or giving—donations can come from pooled, invested assets (including appreciated stock), which affects tax outcomes, liquidity and potential future flows of shares or cash to charities and the market.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

Barinthus Biotherapeutics plc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

(CUSIP Number)

Robert Giffen Collins
1901 Ulmerton Road, Suite 400,
Clearwater, FL, 33762
8138178035

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

02/03/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP No.

1

Name of reporting person

International Generosity Foundation Trust

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

FLORIDA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 2,734,189.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 2,734,189.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

2,734,189.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.7 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock
(b)	Name of Issuer: Barinthus Biotherapeutics plc.
(c)	Address of Issuer's Principal Executive Offices: 20400 CENTURY BLVD, SUITE 210, GERMANTOWN, MARYLAND , 20874.
Item 2.	Identity and Background
(a)	International Generosity Foundation Trust
(b)	1901 Ulmerton Road, Suite 400, Clearwater, Florida 33762, USA
(c)	The Reporting Person is a non-profit trust organized under Section 501(c) of the Internal Revenue Code. Its affairs are managed by its trustee.
(d)	The Reporting Person has not been convicted in any criminal proceeding during the last five years.
(e)	The Reporting Person has not been a party to any civil proceeding of a judicial or administrative body of competent jurisdiction during the last five years resulting in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws.
(f)	United States of America
Item 3.	Source and Amount of Funds or Other Consideration
	The securities reported herein were acquired by the Reporting Person through a combination of purchases and transfers. A portion of the securities was acquired using the working capital of the Reporting Person. The Reporting Person is a non-profit trust generally funded through donations, including donor-advised funds. The remaining securities were acquired through transfers or contributions to the Reporting Person and were not acquired through the use of funds.
Item 4.	Purpose of Transaction
	The Reporting Person acquired the securities for investment purposes and in connection with its charitable activities. The Reporting Person may, from time to time, sell or otherwise dispose of some or all of the securities, including to support its charitable purposes, or acquire additional securities, depending on market conditions and other factors. Except as set forth above, the Reporting Person has no present plans or proposals that relate to or would result in any of the actions described in Items 4(a) through (j) of Schedule 13D.
Item 5.	Interest in Securities of the Issuer
(a)	Aggregate Number of Shares Owned: 2,734,189 Percentage of Class of Securities Identified: 6.7
(b)	The Reporting Person has sole voting power with respect to 2,734,189 shares, shared voting power with respect to 0 shares, sole dispositive power with respect to 2,734,189 shares, and shared dispositive power with respect to 0 shares.
(c)	The Reporting Person has not effected any transactions in the securities of the Issuer during the past 60 days.
(d)	No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.
(e)	Not applicable
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	The Reporting Person does not have any contracts, arrangements, understandings or relationships (legal or otherwise) with respect to any securities of the Issuer, other than as described in this Schedule 13D.
Item 7.	Material to be Filed as Exhibits.
	None

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

International Generosity Foundation Trust

Signature:	Robert Giffen Collins
Name/Title:	Robert Giffen Collins
Date:	04/13/2026

FAQ

How many Barinthus Biotherapeutics (BRNS) shares does International Generosity Foundation Trust own?

International Generosity Foundation Trust beneficially owns 2,734,189 shares of Barinthus Biotherapeutics common stock. This stake represents 6.7% of the company’s outstanding common shares, and the trust reports sole voting and sole dispositive power over all of these shares.

What percentage of Barinthus Biotherapeutics (BRNS) does the trust’s 2,734,189 shares represent?

The reported 2,734,189 shares of Barinthus Biotherapeutics common stock represent 6.7% of the outstanding class. This level of beneficial ownership triggers the requirement to file a Schedule 13D to disclose the position and related information to the market.

Who is the reporting person in this Barinthus Biotherapeutics (BRNS) Schedule 13D?

The reporting person is International Generosity Foundation Trust, a non-profit trust organized under Section 501(c) of the Internal Revenue Code. It is based in Clearwater, Florida, and its affairs are managed by a trustee acting on behalf of the trust.

Why did International Generosity Foundation Trust acquire Barinthus Biotherapeutics (BRNS) shares?

The trust acquired Barinthus Biotherapeutics shares for investment purposes and in connection with its charitable activities. It may buy additional shares or sell some or all holdings over time, including to support its charitable mission, depending on market conditions and other factors.

How were the Barinthus Biotherapeutics (BRNS) shares funded by International Generosity Foundation Trust?

The trust acquired the securities using a combination of working capital and contributed shares. Part of the position was purchased with its own funds, while the remainder came from transfers or contributions, including donations and donor-advised fund contributions to the trust.

Does International Generosity Foundation Trust have any special agreements regarding its Barinthus Biotherapeutics (BRNS) stake?

The trust states it has no contracts, arrangements, understandings or relationships regarding Barinthus Biotherapeutics securities beyond what is described in the filing. It also reports that no other person is entitled to dividends or sale proceeds from the reported shares.